Nortriptyline: Nursing Drug Guide, Suicidality & TCA Toxicity & NCLEX Review
On every shift after a new start or dose change, watch for worsening mood, suicidality, and activation—not only dry mouth or constipation. TCA overdose widens QRS and can be fatal; obtain an ECG and activate monitoring when extra tablets are missing. MAOI and serotonergic combinations raise serotonin syndrome risk—verify a 14-day washout before the first dose.
Nortriptyline carries a boxed warning that antidepressants increase suicidal thinking and behavior in children, adolescents, and young adults compared with placebo; nortriptyline is not approved for pediatric patients. Monitor all patients—especially during the first months and at dose changes—for worsening depression, suicidality, agitation, and unusual behavior. TCA overdose can cause fatal dysrhythmias, severe hypotension, seizures, and coma; obtain an ECG immediately when toxicity is suspected. MAO inhibitors (including linezolid) are contraindicated—allow at least 14 days after MAOI discontinuation before starting nortriptyline.
📋 Contents
⚡ Quick facts
💡 Key takeaway
After initiation or titration, document mood and behavior every contact—not only anticholinergic comfort. When daily dose exceeds 100 mg, labeling supports plasma level monitoring (target range 50–150 ng/mL). Any suspected overdose is a cardiac emergency: hold the dose, ECG now, and contact poison control or toxicology per facility protocol.
Most common brand names
Nortriptyline hydrochloride is supplied as oral capsules (10, 25, 50, and 75 mg) and as an oral solution per labeling. Verify strength and formulation on the MAR and pharmacy label.
Common brand names include Pamelor and Aventyl. Nortriptyline is an active metabolite of amitriptyline but is a separate product—do not substitute milligram-for-milligram without prescriber and pharmacy review.
Why we give it — Indications
Prescribing information lists nortriptyline for relief of symptoms of depression; endogenous depressions are more likely to respond than other depressive states. Clinicians may also use TCAs off-label for neuropathic pain or migraine prophylaxis—know the order indication because suicidality surveillance remains mandatory whenever used as an antidepressant.
| Use | Detail |
|---|---|
| Major depression | Label indication; initiate low and increase gradually; maintenance at lowest effective dose |
| Not approved | Pediatric use—boxed warning applies if considered; safety and effectiveness not established in children per labeling |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The mechanism of mood elevation by tricyclic antidepressants is not fully known. Nortriptyline is not a monoamine oxidase inhibitor. Labeling describes inhibition of histamine, serotonin, and acetylcholine activity, interference with catecholamine transport, and combined stimulant and depressant properties. Nurses should expect anticholinergic and cardiovascular effects (tachycardia, conduction changes) plus CNS activation or sedation depending on dose and patient.
Dosing overview
Initiate at a low dose and increase gradually while watching for intolerance, suicidality, and cardiac effects. Doses above 150 mg/day are not recommended per labeling. When doses above 100 mg daily are administered, plasma nortriptyline levels should be monitored and maintained in the optimum range of 50–150 ng/mL.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber or pharmacist if multiple doses are missed, especially after recent titration.
Dosing must be verified against current prescribing information, prescriber order, and local policy. Institutional protocols and product formulations may vary.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Not specified in the reviewed prescribing information | Antidepressant benefit is not immediate—continue suicidality monitoring during early weeks |
| Peak / duration | Not specified in the reviewed prescribing information | Steady clinical assessment matters more than a single timing label for TCAs |
| Half-life | Not specified in the reviewed prescribing information | Quinidine co-administration may prolong nortriptyline half-life and raise AUC per labeling |
| Plasma levels | Target 50–150 ng/mL when dose >100 mg/day | Coordinate trough timing with pharmacy; do not use levels alone to guide acute overdose management |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Screen for bipolar disorder before treating depressive symptoms with antidepressant alone
- Review cardiovascular history, seizure history, urinary retention, narrow-angle glaucoma risk, and fall risk
- Confirm no MAOI or linezolid within 14 days; reconcile SSRIs, tramadol, and other serotonergic agents via medication reconciliation
- Assess baseline mood, sleep, and safety; involve family/caregivers per Medication Guide counseling
Contraindications
- Hypersensitivity to nortriptyline or other dibenzazepines (cross-sensitivity possible)
- Concomitant MAOIs intended to treat psychiatric disorders (14-day washout when switching)
- Starting nortriptyline during linezolid or IV methylene blue therapy (serotonin syndrome risk)
- Acute recovery period after myocardial infarction
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAO inhibitors (linezolid) | Contraindicated—serotonin syndrome and severe reactions | Hold nortriptyline; verify 14-day washout; pharmacist review before restart |
| SSRIs (fluoxetine, sertraline) | CYP2D6 inhibition can raise TCA levels; fluoxetine may need ≥5 weeks washout before TCA start | Coordinate switches with pharmacy; monitor for toxicity (confusion, sedation, wide QRS) |
| Cimetidine, quinidine | Raised nortriptyline plasma concentrations | Notify pharmacist when new order starts; watch for exaggerated adverse effects |
| Alcohol | Potentiation with nortriptyline—may increase suicidal attempts or overdose risk per labeling | Reinforce avoidance; assess ingestion history when behavior changes |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral capsule or oral solution. Total daily dose may be given once daily or in divided doses per prescriber.
- Swallow capsules whole unless pharmacy approves opening for a specific formulation
- Store at controlled room temperature in a tight, child-resistant container per labeling
- Counsel that driving and hazardous tasks may be impaired until individual response is known
Observe closely for clinical worsening, suicidality, and unusual behavior when therapy starts and whenever dose changes—especially in young adults. Report emergent anxiety, insomnia, irritability, hostility, akathisia, hypomania, or mania to the prescriber immediately.
Expected therapeutic response
- Gradual improvement in depressive symptoms over weeks—not immediate
- Stable mood without emergent suicidality, agitation, or manic symptoms
- Stable vitals and ECG without new palpitations, syncope, or conduction abnormalities
Red flags — Stop and act
Escalate urgently for suicidality, serotonin syndrome, cardiac toxicity, or severe anticholinergic compromise.
- New or worsening suicidal ideation, self-harm behavior, or violent impulsivity—immediate safety intervention
- Serotonin syndrome: agitation, hallucinations, tachycardia, labile BP, hyperthermia, tremor, rigidity, diarrhea
- Sustained tachycardia, syncope, wide QRS, or ventricular arrhythmia—suspect TCA toxicity especially with overdose
- Seizures, coma, severe hypotension, or marked mental status change after ingestion or rapid dose escalation
- Acute eye pain or vision changes in patients at risk for angle-closure glaucoma after pupillary dilation
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Dry mouth, constipation, urinary retention | Common anticholinergic effects; worse in elderly | Fall precautions, bowel protocol, monitor urine output |
| Dizziness, sedation, orthostatic hypotension | Common cardiovascular/CNS effects per labeling | Rise slowly; orthostatic vitals; syncope workup if recurrent |
| Tachycardia, arrhythmias, heart block | Serious cardiovascular effects; MI and stroke reported | ECG when symptomatic; hold and notify prescriber |
| Confusion, hallucinations (especially elderly) | Psychiatric/neurologic effects per labeling | Assess orientation; rule out toxicity and serotonin syndrome |
| Seizures, coma (overdose) | Critical toxicity | Activate emergency response; poison control per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Labeling notes pharmacologic similarities among TCAs—consider class adverse reactions when nortriptyline is administered.
Overdose, toxicity, and antidote
Deaths may occur from TCA overdose. Toxicity develops rapidly; hospital monitoring is required as soon as possible. Multiple drug ingestion including alcohol is common.
Critical manifestations
- Cardiac dysrhythmias, severe hypotension, shock, pulmonary edema, convulsions, CNS depression including coma
- ECG: QRS widening (≥0.10 s may indicate severity), conduction blocks, sinus tachycardia
- Agitation, hyperactive reflexes, hyperpyrexia, dilated pupils, or other acute adverse effects
Management (nursing priorities)
Obtain ECG and initiate cardiac monitoring immediately. Secure airway, IV access, gastric decontamination with large-volume lavage followed by activated charcoal when indicated—emesis is contraindicated. Minimum six hours observation with monitoring; extend if toxicity signs appear. Sodium bicarbonate may be used per toxicology to maintain serum pH 7.45–7.55 for QRS prolongation. No specific antidote is listed in the reviewed prescribing information—management is supportive with poison control or toxicology guidance.
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance when overdose is suspected. Psychiatric follow-up is often appropriate because overdose may be deliberate.
Look-alike / sound-alike and error prevention
- Nortriptyline vs amitriptyline—both TCAs; different sedating profiles and monitoring—verify active ingredient on every administration
- Nortriptyline vs imipramine / desipramine—sound-alike TCA names on MARs
- Capsule strength confusion—10, 25, 50, 75 mg capsules; independent double-check when dose exceeds 100 mg/day
- SSRI plus TCA without washout—raises toxicity risk; document stop dates
No specific look-alike/sound-alike pair beyond TCA class names was identified in the reviewed sources, but standard medication-name verification still applies.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Timing | May be once daily or divided; less sedating than some TCAs but still monitor falls |
| Plasma level | When dose >100 mg/day, coordinate trough level with pharmacy (target 50–150 ng/mL) |
| Abrupt stop | After prolonged therapy, abrupt stop may cause nausea, headache, malaise—taper per prescriber |
| Quantity limits | Prescribe smallest quantity consistent with good management because overdose risk is significant |
| Ask pharmacy when | SSRI-to-TCA switches, MAOI history, QRS widening, or orders above 150 mg/day |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Children & adolescents | Not approved; boxed warning for suicidality if antidepressant considered—balance risk with clinical need |
| Young adults (18–24) | Higher suicidality risk versus placebo in short-term studies—intensify monitoring at initiation and dose changes |
| Older adults | 30–50 mg/day usual range; confusional states and arrhythmias reported; higher metabolite levels possible |
| Cardiovascular disease | Give only under close supervision—sinus tachycardia and conduction prolongation; MI, arrhythmia, stroke reported |
| Pregnancy / lactation | Safe use not established—weigh benefits and hazards; LactMed: low milk levels, often preferred TCA during breastfeeding with infant monitoring |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mood, behavior, suicidality, sleep, and functional status—especially first months and after dose changes
- Heart rate, blood pressure, orthostatic symptoms, and ECG when cardiac history or overdose concern exists
- Anticholinergic burden: mental status, bowel function, urine output, temperature
- Plasma nortriptyline level when daily dose exceeds 100 mg (target 50–150 ng/mL per labeling)
Document
- Baseline and follow-up safety assessments; family/caregiver education on warning symptoms
- Dose, route, time, formulation strength, and patient response
- ECG, plasma level results, and poison-control consultation when toxicity is suspected
Patient teaching
- Antidepressants may increase suicidal thoughts in some people—seek help immediately for worsening depression, agitation, panic, insomnia, irritability, hostility, or thoughts of self-harm
- Do not stop suddenly without talking to the prescriber; withdrawal symptoms can occur after prolonged use
- Rise slowly from sitting or lying down; avoid alcohol and other sedatives unless approved
- Report dry mouth, constipation, urinary difficulty, palpitations, dizziness, eye pain, or vision changes
- Full antidepressant benefit may take weeks—keep follow-up appointments
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- MAOI, linezolid, or IV methylene blue within 14 days (or active therapy) without documented washout plan
- Active suicidal plan, overdose ingestion, or emergent mania/psychosis
- Symptomatic wide QRS, unstable arrhythmia, or seizure after recent dose
- Suspected serotonin syndrome (fever, rigidity, clonus, agitation with serotonergic co-meds)
- Acute recovery phase post myocardial infarction (contraindicated)
- Ordered daily dose above 150 mg/day, or above 100 mg/day without plasma level monitoring when required by protocol
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Nortriptyline is a secondary amine TCA often chosen when sedation must be minimized, but suicidality surveillance and fatal overdose risk remain unchanged. Build antidepressant safety into admission reconciliation and every dose increase—not only at discharge.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and indication (depression vs pain pathway)
- MAOI/linezolid history and recent SSRI therapy documented
- Suicidality screen current when initiating or changing dose
- Verify capsule strength and total daily milligrams (max 150 mg/day per labeling)
2. High-alert and safety badge
High-risk antidepressant — suicidality boxed warning + fatal TCA overdose toxicityTreat suspected overdose as monitored cardiac emergency. Prescriptions should be the smallest quantity consistent with good patient management per labeling.
3. Clinical workflow: hold and question rules
- If fluoxetine was stopped less than five weeks ago and nortriptyline is ordered, hold and call pharmacy per labeling interaction guidance
- If family reports new impulsivity or insomnia after dose increase, notify prescriber the same day
- Any missing tablets with QRS ≥0.10 s triggers ECG monitoring and toxicology consult
4. Critical teach-back questions
- “What mood or behavior changes should you report right away?” (Worsening depression, suicidal thoughts, agitation, insomnia, irritability, unusual behavior.)
- “What should you do if you take more capsules than prescribed?” (Seek emergency care and contact local poison control or toxicology per facility guidance—even without symptoms.)
5. Care coordination
Pharmacist: MAOI washout, SSRI-to-TCA switches, plasma level timing when dose >100 mg/day, and overdose pathways
Psychiatry / prescriber: Suicidality escalation, bipolar screening, and antidepressant class changes
🧠 Quick mental checklist
- Is this a new start, dose increase, or switch from an SSRI or MAOI?
- Any suicidal ideation, agitation, insomnia, or behavioral change since the last dose?
- Heart rate, blood pressure, orthostatics, and ECG if ingestion or cardiac history?
- Is total daily dose ≤150 mg, with level monitoring planned if >100 mg?
- If overdose suspected, is monitoring started and poison control contacted per protocol?
Nortriptyline NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for nortriptyline with a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), ECG trend interpretation, MAOI washout cloze, ordered overdose steps, and a matrix sorting suicidality versus cardiac versus anticholinergic findings—recognise cues → analyse → prioritise → act → evaluate outcomes around TCA toxicity and antidepressant monitoring.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Nortriptyline 75 mg PO daily (25 mg TID) — started 3 days ago (increased from 50 mg/day two days ago)
- Fluoxetine 20 mg PO daily — discontinued 10 days ago per MAR
- Linezolid 600 mg PO q12h — completed course 18 days ago
- Docusate 100 mg PO BID — for constipation
- Admission ECG: sinus rhythm, QRS 0.08 s, QTc 420 ms
- Today 1400 (after reported extra tablets): ECG QRS 0.11 s, sinus tachycardia 118/min
- BMP: sodium 138, potassium 4.0, creatinine 0.9 mg/dL
- No serum TCA level available on panel
- 1030: BP 108/62, HR 88, RR 16, SpO2 98% on room air, temp 36.8 °C
- 1400: BP 92/58, HR 118, RR 18, SpO2 97%, temp 37.1 °C
- Orthostatics: lying BP 110/64 → standing BP 88/54 with dizziness
- 72-year-old on unit for major depression; family at bedside
- 0900: Patient denies suicidal plan; mood “about the same”
- 1330: Restless, irritable, insomnia last night; states “my mind races”
- 1345: Nurse found 8 extra 25 mg capsules missing from blister pack; patient admits taking them “to sleep”
- 1400: Dry mucous membranes, constipation 3 days, assisted ambulation for dizziness
Answer key & rationale
Frequently asked questions
Why does nortriptyline have a boxed warning for suicidality?
Antidepressants, including nortriptyline, increased suicidal thinking and behavior compared with placebo in short-term studies in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients of all ages starting therapy should be monitored for clinical worsening, suicidality, and unusual changes in behavior, especially during initial months and at dose changes.
How long must a nurse wait after stopping an MAOI before starting nortriptyline?
Nortriptyline is contraindicated with monoamine oxidase inhibitors intended to treat psychiatric disorders. When replacing an MAOI with nortriptyline, allow a minimum of 14 days after the MAOI is discontinued before initiating nortriptyline, then titrate cautiously per prescribing information.
What ECG changes suggest TCA overdose toxicity?
Labeling states QRS axis or width changes are clinically significant indicators of tricyclic antidepressant toxicity. A rightward terminal QRS shift with prolonged QT and sinus tachycardia are specific and sensitive for first-generation TCA overdose. Obtain an ECG immediately when overdose is suspected.
Is nortriptyline safe during breastfeeding?
LactMed reports low milk levels; infant serum nortriptyline is usually undetectable though metabolites may appear at low levels. Published follow-up with maternal doses 25–175 mg daily has not reported adverse reactions in infants, but monitor for drowsiness, poor feeding, or irritability and coordinate with the prescriber.
Why are older adults at higher risk with nortriptyline?
Labeling recommends total daily doses of 30–50 mg for elderly patients, with confusional states and cardiovascular fluctuations reported. Higher plasma concentrations of active metabolite 10-hydroxynortriptyline have been reported in elderly patients—use the smallest effective dose and monitor falls, orthostasis, and ECG when cardiac disease is present.
References
-
U.S. National Library of Medicine. Nortriptyline hydrochloride capsule — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9386627f-3522-425b-b0b0-f4d9d30ad98e
-
U.S. Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidality-children-and-adolescents-being-treated-antidepressant
-
Drugs and Lactation Database (LactMed). Nortriptyline. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501176/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.